Keeping progress in oncology on the agenda: ESMO honours recipients of its 2020 awards
The global coronavirus pandemic has disrupted cancer research, prevention and treatment to an extent never seen before.
ESMO Media Releases
ESMO Immuno-Oncology Virtual Congress 2020
The ESMO Immuno-Oncology Congress 2020, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as a virtual meeting.
ESMO Asia Virtual Congress 2020, 20-22 November
The ESMO Asia Congress 2020, the leading scientific platform in the Asia-Pacific region, will be held as a virtual meeting.
MAP Congress 2020: Molecular Analysis for Precision Oncology
The Molecular Analysis for Precision oncology (MAP) Congress is designed to answer the critical question about how to integrate the wealth of information coming from the analysis of tumour samples into daily practice.
Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.
First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor Positive Early Breast Cancer
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
No Benefit for Post-operative Radiotherapy in Non-small-cell Lung Cancer
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020.
New First-Line Treatment Option for Metastatic Kidney Cancer, According to Results of Phase 3 Study
The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.
Access to Cancer Medicines and Clinical Trials Show Stark Variations Across Europe
Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries
COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing
Data from latest research presented at the ESMO Virtual Congress 2020
Programme Highlights of the ESMO Virtual Congress 2020
The full scientific programme of the ESMO Congress 2020 (19-21 September) is now available online.
ESMO Announces Winners of its Awards 2020
The European Society for Medical Oncology has announced the winners of the ESMO awards 2020.